Teva Pharmaceutical Industries Ltd

Climate Impact & Sustainability Data (2022)

Total Carbon Emissions:498,641 tCO2e/year (Scope 1 & 2 in 2022)

Renewable Energy Share:41% of total energy use (2022)

Water Consumption:1,338 ML/year (Areas projected to be in water stress in 2022)

Waste Generated:111,194 metric tons/year (2022)

24% reduction in absolute scope 1 and 2 GHG emissions (vs. 2019)
12% reduction in absolute scope 3 GHG emissions (vs. 2020)
Achieved 10% increase in energy efficiency by revenue (kWh/USD revenue) by 2030 (vs. 2020)
Increased total proportion of electricity purchased or generated from renewable sources by 8% (vs. 2021) to 41%
Achieved 17% reduction in total water withdrawal in areas projected to be in water stress by 2030 (vs. 2020)
32% reduction in total waste generated (vs. 2020) and 3% increase in proportion of waste recovered (vs. 2020)

5 access to medicines programs launched (63% of 8 access programs /2025 target)
533.7M units (worth $699.6M) of medicines donated to patients in need
90% of critical positions filled internally, 60% of which were filled by identified successors
$44B in savings from Teva’s generic medicines across 21 countries
210 clinical trials conducted for generic and innovative medicines
21 new regulatory submissions in low- and middle-income countries (LMICs) (28% of 75 submissions/2025 target)
72.6 score on Bloomberg Gender-Equality Index (vs. 52.7 in 2021)
Improved employee safety performance: 50% reduction in process safety event rate (vs. 2021)
80% reduction in total recordable incident rate over the last 10 years
71% of employees feel engaged and connected to Teva
82% employee satisfaction with Teva’s inclusion and diversity practices

Long-term Goals:

Medium-term Goals:

Reduce absolute scope 1 and 2 GHG emissions by 46% by 2030 (vs. 2019)
Reduce absolute scope 3 GHG emissions by 25% by 2030 (vs. 2020)
Increase total proportion of electricity purchased or generated from renewable sources to 50% by 2030
Reduce total water withdrawal by 10% in areas projected to be in water stress by 2030 (vs. 2020)
Launch eight access programs by 2025

Short-term Goals:

Developed alternative sourcing strategies
Implemented technologies and systems to identify and mitigate suspected counterfeits
Finalized terms of proposed nationwide opioid settlement
Minimizing antimicrobial discharges by assessing Teva sites and supply chain
Established decarbonization plan, including energy efficiency, renewable energy, and network optimization
Formalized water conservation programs in water-stressed areas
Robust compliance program with risk-based training, third-party screening, and monitoring dashboards
ISO 27001 certification, cybersecurity trainings, and incident response mechanisms

Supplier Audits: 56% of critical suppliers assessed by EcoVadis in 2022; 6 PSCI audits conducted.

Frameworks Used: GRI, SASB, TCFD, UNGC

Certifications: ISO 14001, ISO 27001

Third-party Assurance: DNV